The secondary end point was DMFS
While peptide drugs may have higher acquisition costs, they often provide clinical benefits that can reduce overall healthcare costs
Her BMI was 24.5, just shy of the overweight threshold (and far from the FDAs threshold of 30), but her physician OKd a low dose of a GLP-1
However, this still requires further investigation
If you fall into the slower-responder category, reviewing our detailed guide on why you might not be losing weight on semaglutide can help identify whether something actionable is holding you back or whether you simply need more time at a higher dose
de Oliveira FF, Chen ES, Smith MC, Bertolucci PHF